Skip to main content Skip to search Skip to main navigation

PIC/S: What’s planned in terms of GMP?

The Pharmaceutical Inspection Cooperation Scheme (PIC/S) has published its 2022 work plan with the organization’s planned actions for this year. Not only does PIC/S plan to resume its assessments for membership application but also to revise or draft new GMP guidelines.

Revision plans for GMP guidelines in close alignment with the EU include:

  • The finalisation of Annex 1 for sterile manufacturing in alignment with the new EU Annex 1, which is scheduled to be released around September this year. PIC/S is planning to establish an Expert Circle on Sterile Products to train inspectors on the new requirements coming along with the new Annex 1.
  • The revision of the GMP Guide Chapter 1 on Pharmaceutical Quality Systems is planned to be continued/finalized in close co-operation with the EMA’s Inspectors Working Goup (IWG) on GMDP. This is also anticipated for Chapter 4 on Documentation), Annex 11 on Computerised Systems and Annexes 4 and 5 on Veterinary Medicinal Products (VMPs and Immunological VMPs.
  • The publication of concept paper on veterinary specific GMP guidelines in the PIC/S Working group on VMPs.
  • The monitoring of the EU Annex 21 (importation of medicinal products) through the participation of Swissmedic in the Drafting Group. Once finalised, the Committee will need to decide whether to adapt this Annex for PIC/S purposes.

PIC/S GMDP-related guidance documents to be further revised or developed:

  • PE 010-4 PIC/S Guide to Good Practices for the Preparation of Medicinal Products in
  • Healthcare Establishments
  • PI 006-3 Revision of PIC/S Recommendations on Validation Master Plan; Installation
  • and Operational Qualification; Non-Sterile Process Validation; and Cleaning Validation
  • PI 007 Recommendation on Validation of Aseptic Processes
  • PI 011 PIC/S Guidance on Good Practices for Computerised Systems in Regulated GxP Environments
  • PI 013 PIC/S Inspection Report
  • PI 023-2 Aide Mémoire on Inspection of Quality Control Laboratories
  • PI 025 Aide Mémoire on Medicinal Gases
  • PI 030-1 Aide Mémoire on the Inspection of APIs
  • PI 043-2 PIC/S Aide Mémoire on Controlling Cross-Contamination in Shared Facilities
  • PI 050 Aide Mémoire on PIC/S Data Integrity System-Specific Guidance: Chromeleon 7 Chromatography Data Systems and Server/Client Systems
  • PI 019 PIC/S Site Master File for Source Plasma Establishments
  • PI 020 PIC/S Site Master File for Plasma Warehouses

For GDP:

An Aide Mémoire on Inspection of Manufacturers and Wholesale Distributors for Compliance with GDP along with a Q&A for the PIC/S GDP Guide will be finalised by 2022.

Membership assessment:
With assessments and reassessments for membership put on hold for the last two years, these countries will be reassessed, which is the final step for membership: Chinese Taipei’s Food and Drug Administration (TFDA), Indonesia’s National Agency of Food and Drug Control (ADFC), New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe), and South Africa’s Health Products Regulatory Authority (SAHPRA).

The PIC/S Committee plans to meet face-to-face in Dublin, Ireland,  on 3 October 2022 in connection with PIC/S’ 50th Anniversary, which will be hosted by the Irish regulatory authority HPRA.


Source:

PIC/S: Work Plan 2022

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next